메뉴 건너뛰기




Volumn 16, Issue 1, 2016, Pages

AKT1E17K mutation profiling in breast cancer: Prevalence, concurrent oncogenic alterations, and blood-based detection

Author keywords

AKT1E17K mutation; Blood based mutation detection; Breast cancer

Indexed keywords

ESTROGEN RECEPTOR; AKT1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE B;

EID: 84991666714     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2626-1     Document Type: Article
Times cited : (62)

References (48)
  • 2
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92.
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3    Fuchs, H.4    Paton, V.5    Bajamonde, A.6
  • 3
    • 84861527388 scopus 로고    scopus 로고
    • The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
    • Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346-52.
    • (2012) Nature , vol.486 , pp. 346-352
    • Curtis, C.1    Shah, S.P.2    Chin, S.F.3    Turashvili, G.4    Rueda, O.M.5    Dunning, M.J.6
  • 7
    • 56749168073 scopus 로고    scopus 로고
    • Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain
    • Landgraf KE, Pilling C, Falke JJ. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. Biochemistry. 2008;47:12260-9.
    • (2008) Biochemistry , vol.47 , pp. 12260-12269
    • Landgraf, K.E.1    Pilling, C.2    Falke, J.J.3
  • 8
    • 67649868092 scopus 로고    scopus 로고
    • The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas
    • Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y, et al. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer. 2009;101:145-8.
    • (2009) Br J Cancer , vol.101 , pp. 145-148
    • Shoji, K.1    Oda, K.2    Nakagawa, S.3    Hosokawa, S.4    Nagae, G.5    Uehara, Y.6
  • 9
    • 43249115083 scopus 로고    scopus 로고
    • Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
    • Kim MS, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer. 2008;98:1533-5.
    • (2008) Br J Cancer , vol.98 , pp. 1533-1535
    • Kim, M.S.1    Jeong, E.G.2    Yoo, N.J.3    Lee, S.H.4
  • 10
    • 41649108534 scopus 로고    scopus 로고
    • Following the tracks of AKT1 gene
    • Vogiatzi P, Giordano A. Following the tracks of AKT1 gene. Cancer Biol Ther. 2007;6:1521-4.
    • (2007) Cancer Biol Ther , vol.6 , pp. 1521-1524
    • Vogiatzi, P.1    Giordano, A.2
  • 11
    • 0036632368 scopus 로고    scopus 로고
    • The phosphatidylinositol 3-kinase AKT pathway in human cancer
    • Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489-501.
    • (2002) Nat Rev Cancer , vol.2 , pp. 489-501
    • Vivanco, I.1    Sawyers, C.L.2
  • 12
    • 84863447451 scopus 로고    scopus 로고
    • PIK3CA/AKT1 mutations in breast carcinoma: a comprehensive review of experimental and clinical studies
    • Troxell ML. PIK3CA/AKT1 mutations in breast carcinoma: a comprehensive review of experimental and clinical studies. J Clinic Experiment Pathol. 2012;S1:002.
    • (2012) J Clinic Experiment Pathol , vol.S1 , pp. 002
    • Troxell, M.L.1
  • 14
    • 51049118140 scopus 로고    scopus 로고
    • An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
    • Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68:6084-91.
    • (2008) Cancer Res , vol.68 , pp. 6084-6091
    • Stemke-Hale, K.1    Gonzalez-Angulo, A.M.2    Lluch, A.3    Neve, R.M.4    Kuo, W.L.5    Davies, M.6
  • 16
    • 73949156234 scopus 로고    scopus 로고
    • High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast
    • Troxell ML, Levine J, Beadling C, Warrick A, Dunlap J, Presnell A, et al. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod Pathol. 2010;23:27-37.
    • (2010) Mod Pathol , vol.23 , pp. 27-37
    • Troxell, M.L.1    Levine, J.2    Beadling, C.3    Warrick, A.4    Dunlap, J.5    Presnell, A.6
  • 17
    • 20144387695 scopus 로고    scopus 로고
    • PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
    • Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005;65:2554-9.
    • (2005) Cancer Res , vol.65 , pp. 2554-2559
    • Saal, L.H.1    Holm, K.2    Maurer, M.3    Memeo, L.4    Su, T.5    Wang, X.6
  • 18
    • 84886440334 scopus 로고    scopus 로고
    • PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system
    • Beaver JA, Gustin JP, Yi KH, Rajpurohit A, Thomas M, Gilbert SF, et al. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin Cancer Res. 2013;19:5413-22.
    • (2013) Clin Cancer Res , vol.19 , pp. 5413-5422
    • Beaver, J.A.1    Gustin, J.P.2    Yi, K.H.3    Rajpurohit, A.4    Thomas, M.5    Gilbert, S.F.6
  • 19
    • 84899811319 scopus 로고    scopus 로고
    • Patients and Methods of the PATH Biobank-A Resource for Breast Cancer Research
    • Waldmann A, Anzeneder T, Katalinic A. Patients and Methods of the PATH Biobank-A Resource for Breast Cancer Research. Geburtshilfe Frauenheilkd. 2014;74:361-9.
    • (2014) Geburtshilfe Frauenheilkd , vol.74 , pp. 361-369
    • Waldmann, A.1    Anzeneder, T.2    Katalinic, A.3
  • 20
    • 84887491073 scopus 로고    scopus 로고
    • Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
    • Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023-31.
    • (2013) Nat Biotechnol , vol.31 , pp. 1023-1031
    • Frampton, G.M.1    Fichtenholtz, A.2    Otto, G.A.3    Wang, K.4    Downing, S.R.5    He, J.6
  • 21
    • 84867131355 scopus 로고    scopus 로고
    • Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers
    • Brouckaert O, Laenen A, Vanderhaegen J, Wildiers H, Leunen K, Amant F, et al. Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol. 2012;23:2578-84.
    • (2012) Ann Oncol , vol.23 , pp. 2578-2584
    • Brouckaert, O.1    Laenen, A.2    Vanderhaegen, J.3    Wildiers, H.4    Leunen, K.5    Amant, F.6
  • 22
    • 84991700305 scopus 로고
    • Controlling the false discovery rate: a practical and powerful approach to multiple testing
    • Benjamani Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B. 1995;57:289-300.
    • (1995) J Roy Statist Soc Ser B , vol.57 , pp. 289-300
    • Benjamani, Y.1    Hochberg, Y.2
  • 24
    • 84857921336 scopus 로고    scopus 로고
    • Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes
    • Boyault S, Drouet Y, Navarro C, Bachelot T, Lasset C, Treilleux I, et al. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat. 2012;132:29-39.
    • (2012) Breast Cancer Res Treat , vol.132 , pp. 29-39
    • Boyault, S.1    Drouet, Y.2    Navarro, C.3    Bachelot, T.4    Lasset, C.5    Treilleux, I.6
  • 25
    • 84868682387 scopus 로고    scopus 로고
    • Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers
    • Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, Riisnaes R, et al. Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One. 2012;7:e47020.
    • (2012) PLoS One , vol.7
    • Perkins, G.1    Yap, T.A.2    Pope, L.3    Cassidy, A.M.4    Dukes, J.P.5    Riisnaes, R.6
  • 28
    • 70349741007 scopus 로고    scopus 로고
    • Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA
    • Kadota M, Sato M, Duncan B, Ooshima A, Yang HH, Diaz-Meyer N, et al. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res. 2009;69:7357-65.
    • (2009) Cancer Res , vol.69 , pp. 7357-7365
    • Kadota, M.1    Sato, M.2    Duncan, B.3    Ooshima, A.4    Yang, H.H.5    Diaz-Meyer, N.6
  • 29
    • 77951586944 scopus 로고    scopus 로고
    • Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations
    • Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, et al. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene. 2010;29:2337-45.
    • (2010) Oncogene , vol.29 , pp. 2337-2345
    • Lauring, J.1    Cosgrove, D.P.2    Fontana, S.3    Gustin, J.P.4    Konishi, H.5    Abukhdeir, A.M.6
  • 30
    • 77955660663 scopus 로고    scopus 로고
    • Diverse somatic mutation patterns and pathway alterations in human cancers
    • Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466:869-73.
    • (2010) Nature , vol.466 , pp. 869-873
    • Kan, Z.1    Jaiswal, B.S.2    Stinson, J.3    Janakiraman, V.4    Bhatt, D.5    Stern, H.M.6
  • 31
    • 84863441069 scopus 로고    scopus 로고
    • Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions
    • Troxell ML, Brunner AL, Neff T, Warrick A, Beadling C, Montgomery K, et al. Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions. Mod Pathol. 2012;25:930-7.
    • (2012) Mod Pathol , vol.25 , pp. 930-937
    • Troxell, M.L.1    Brunner, A.L.2    Neff, T.3    Warrick, A.4    Beadling, C.5    Montgomery, K.6
  • 32
    • 84863983915 scopus 로고    scopus 로고
    • Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
    • Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat. 2012;134:333-43.
    • (2012) Breast Cancer Res Treat , vol.134 , pp. 333-343
    • Santarpia, L.1    Qi, Y.2    Stemke-Hale, K.3    Wang, B.4    Young, E.J.5    Booser, D.J.6
  • 33
    • 84866736379 scopus 로고    scopus 로고
    • Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer
    • Arnedos M, Scott V, Job B, De La Cruz J, Commo F, Mathieu MC, et al. Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. Eur J Cancer. 2012;48:2293-9.
    • (2012) Eur J Cancer , vol.48 , pp. 2293-2299
    • Arnedos, M.1    Scott, V.2    Job, B.3    De La Cruz, J.4    Commo, F.5    Mathieu, M.C.6
  • 34
  • 36
    • 84873724746 scopus 로고    scopus 로고
    • PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs
    • Ross RL, Askham JM, Knowles MA. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs. Oncogene. 2013;32:768-76.
    • (2013) Oncogene , vol.32 , pp. 768-776
    • Ross, R.L.1    Askham, J.M.2    Knowles, M.A.3
  • 37
    • 84927620697 scopus 로고    scopus 로고
    • PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer
    • Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol. 2015;33:1334-9.
    • (2015) J Clin Oncol , vol.33 , pp. 1334-1339
    • Majewski, I.J.1    Nuciforo, P.2    Mittempergher, L.3    Bosma, A.J.4    Eidtmann, H.5    Holmes, E.6
  • 40
  • 41
    • 34247337993 scopus 로고    scopus 로고
    • Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients
    • Daniotti M, Vallacchi V, Rivoltini L, Patuzzo R, Santinami M, Arienti F, et al. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer. 2007;120:2439-44.
    • (2007) Int J Cancer , vol.120 , pp. 2439-2444
    • Daniotti, M.1    Vallacchi, V.2    Rivoltini, L.3    Patuzzo, R.4    Santinami, M.5    Arienti, F.6
  • 42
    • 4143133293 scopus 로고    scopus 로고
    • Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers
    • Wang JY, Hsieh JS, Chang MY, Huang TJ, Chen FM, Cheng TL, et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg. 2004;28: 721-6.
    • (2004) World J Surg , vol.28 , pp. 721-726
    • Wang, J.Y.1    Hsieh, J.S.2    Chang, M.Y.3    Huang, T.J.4    Chen, F.M.5    Cheng, T.L.6
  • 44
    • 2342527930 scopus 로고    scopus 로고
    • Activation of Akt-1 (PKB-a) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion
    • Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt-1 (PKB-a) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res. 2004;64:3171-8.
    • (2004) Cancer Res , vol.64 , pp. 3171-3178
    • Hutchinson, J.N.1    Jin, J.2    Cardiff, R.D.3    Woodgett, J.R.4    Muller, W.J.5
  • 45
    • 84862738897 scopus 로고    scopus 로고
    • Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background
    • Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012;11:873-87.
    • (2012) Mol Cancer Ther , vol.11 , pp. 873-887
    • Davies, B.R.1    Greenwood, H.2    Dudley, P.3    Crafter, C.4    Yu, D.H.5    Zhang, J.6
  • 46
    • 77954615408 scopus 로고    scopus 로고
    • MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo
    • Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9:1956-67.
    • (2010) Mol Cancer Ther , vol.9 , pp. 1956-1967
    • Hirai, H.1    Sootome, H.2    Nakatsuru, Y.3    Miyama, K.4    Taguchi, S.5    Tsujioka, K.6
  • 47
    • 84875804031 scopus 로고    scopus 로고
    • Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models
    • Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J, et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res. 2013;19:1760-72.
    • (2013) Clin Cancer Res , vol.19 , pp. 1760-1772
    • Lin, J.1    Sampath, D.2    Nannini, M.A.3    Lee, B.B.4    Degtyarev, M.5    Oeh, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.